Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma

Published:2014-12-09 Issue:5 Volume:121 Page:673-680
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Sherman William H.¹,Chu Kyung²,Chabot John¹³,Allendorf John¹⁴,Schrope Beth Ann¹³,Hecht Elizabeth¹⁵,Jin Brian¹⁵,Leung David¹⁵,Remotti Helen¹⁶,Addeo Gisella¹⁷,Postolov Inna,Tsai Wei¹⁸,Fine Robert L.¹⁹

Affiliation:

1. Pancreas Center; Columbia University; New York New York

2. Department of Medicine; New York University; New York New York

3. Department of Surgery; Columbia University; New York New York

4. Department of Surgery; Winthrop University Hospital; Mineola New York

5. Department of Radiology; Columbia University; New York New York

6. Department of Pathology; Columbia University; New York New York

7. Department of Radiation Oncology; Columbia University; New York New York

8. Department of Biostatistics; Columbia University; New York New York

9. Department of Medicine; Columbia University; New York New York

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference36 articles.

1. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial;Oettle;JAMA,2007

2. Preoperative gemcitabine-based chemoradiation therapy for patients with resectable adenocarcinoma of the pancreatic head;Evans;J Clin Oncol,2008

3. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response;Turrini;Eur J Surg Oncol,2010

4. Margin clearance and outcome in resected pancreatic cancer;Chang;J Clin Oncol,2009

5. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection;Campbell;Histopathology,2009

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma;American Journal of Clinical Oncology;2023-12-22

2. Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma;Pancreas;2023-05

3. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data;The Oncologist;2022-11-11

4. Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma;Pancreas;2022-10

5. High local failure rates despite high margin‐negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi‐agent chemotherapy;Cancer Medicine;2022-02-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3